Repeal campaigns stall in Arizona as Idaho medical cannabis activists oversubscribe their ballot push, fresh research on legalisation arrests lands, and the industry’s medical-marketing claims and Tilray’s expansion playbook draw scrutiny.
Reclassification confusion, an IPO revival in cannabis pharma and a contentious DEA registration form dominate today’s cannabis news, alongside fresh European consolidation and a return of investor focus on the sector’s ETFs.
Reform momentum builds on both sides of the Atlantic as Richard Branson presses for UK cannabis change, Indiana’s governor signals openness to legalisation, and analysts map the banking access unlocked by US rescheduling.
Today’s cannabis briefing covers the fallout from the US Justice Department’s Schedule III order, fresh travel guidance for UK medical patients, California’s ten-year legalisation milestone, environmental scrutiny at a Trulieve mega-grow, and a notable state-level legalisation recommendation in North Carolina.
Dr John Lucas is stepping down in order to pursue other business interests.
Research studies of LED spectra and intensity have shown a positive impact on floral cannabis yield.
Toxicological studies suggest the average daily intake of isolated CBD should be well below current guidelines.
Ramm Pharma said the acquisition will give it an additional foothold into the European market.
The company said the approval has bolstered its position in Europe.
